

NEXT GENERATION SEQUENCING: EMERGING CLINICAL APPLICATIONS AND GLOBAL MARKETS



BIO126A
July 2013

John Bergin
Project Analyst

ISBN: 1-56965-448-4

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE	3
SCOPE AND FORMAT	3
METHODOLOGY	4
INFORMATION SOURCES	4
RELATED BCC REPORTS	4
ANALYST CREDENTIALS	4
BCC ONLINE SERVICES	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, THROUGH 2018 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, 2012-2018 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	11
INTRODUCTION	11
<i>TABLE 1 REPORT SCOPE</i>	11
CLINICAL NEXT GENERATION SEQUENCING MARKETS	12
<i>TABLE 2 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE, THROUGH 2018 (\$ MILLIONS)</i>	12
CLINICAL NEXT GENERATION SEQUENCING GROWTH DRIVING FORCES	13
TECHNOLOGY DRIVERS	13
<i>TABLE 3 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT GENERATION SEQUENCING</i>	13
MARKET DRIVERS	14
<i>TABLE 4 CLINICAL NEXT GENERATION SEQUENCING MARKET DRIVING FORCES</i>	15
CLINICAL NEXT GENERATION SEQUENCING APPLICATIONS	15
<i>TABLE 5 CLINICAL NEXT GENERATION SEQUENCING APPLICATION STATUS</i>	16
CLINICAL NEXT GENERATION SEQUENCING INDUSTRY	16
<i>TABLE 6 KEY DIAGNOSTIC NEXT GENERATION SEQUENCING INDUSTRY PARTICIPANTS BY SECTOR</i>	17
CHAPTER 4 TECHNOLOGIES	20
IMPORTANCE OF DNA	20
<i>TABLE 7 DNA CHEMICAL BUILDING BLOCKS</i>	20
<i>TABLE 8 DNA TRANSLATION AND TRANSCRIPTION</i>	20
<i>TABLE 9 LONG-RANGE DNA STRUCTURE</i>	21
GENETIC VARIATION AND ANALYSIS	22
<i>TABLE 10 GENETIC VARIANT TYPES</i>	22
GENETIC ANALYSIS TECHNOLOGIES	23
<i>TABLE 11 IMPORTANT MOLECULAR DIAGNOSTIC PLATFORMS BY COMPANY</i>	23

TOPIC	PAGE NO.
NEXT GENERATION SEQUENCING IN CLINICAL APPLICATIONS	24
<i>TABLE 12 GENETIC TESTING EVOLUTION</i>	24
<i>TABLE 13 KEY NEAR- TO MID-TERM SEGMENTS FOR NEXT GENERATION SEQUENCING DIAGNOSTICS</i>	25
NEXT GENERATION SEQUENCING TECHNOLOGIES	26
HISTORY OF DNA SEQUENCING	26
<i>TABLE 14 DNA SEQUENCING HISTORICAL TIMELINE, 1977-2013</i>	27
<i>TABLE 15 SEQUENCING TECHNOLOGY DEVELOPMENT, 1990-2013</i>	32
<i>TABLE 16 EFFECT OF NEW SEQUENCING TECHNOLOGIES ON COST AND TIME TO SEQUENCE A SINGLE HUMAN GENOME, 2001 AND 2013 (\$)</i>	33
SANGER SEQUENCING TECHNOLOGY	33
<i>TABLE 17 SANGER SEQUENCING SUMMARY</i>	33
<i>TABLE 18 SANGER SEQUENCING IMPROVEMENTS</i>	34
NEXT GENERATION SEQUENCING PLATFORMS	34
<i>TABLE 19 NEXT GENERATION SEQUENCING TECHNOLOGIES</i>	35
<i>TABLE 20 ROCHE NEXT GENERATION SEQUENCING WORKFLOW</i>	35
<i>TABLE 21 ILLUMINA NEXT GENERATION SEQUENCING WORKFLOW</i>	36
<i>TABLE 22 LIFE TECHNOLOGIES NEXT GENERATION SEQUENCING WORKFLOW</i>	37
BENCHTOP SEQUENCERS	38
<i>TABLE 23 BENCHTOP SEQUENCER PLATFORMS , 2010-2012</i>	38
INFORMATICS TECHNOLOGIES	39
<i>TABLE 24 NEXT GENERATION SEQUENCING BIOINFORMATICS WORKFLOW</i>	39
BASE CALLING	40
MAPPING TO A REFERENCE SEQUENCE	40
<i>TABLE 25 SEQUENCE ANNOTATION STEPS</i>	41
VARIANT ANALYSIS	41
FUTURE TECHNOLOGY CHALLENGES	42
<i>TABLE 26 FUTURE CHALLENGES FOR IMPLEMENTING CLINICAL NEXT GENERATION SEQUENCING</i>	42
TOP TEN CLINICAL NEXT GENERATION SEQUENCING INITIATIVES	43
<i>TABLE 27 TOP 10 CLINICAL NEXT GENERATION SEQUENCING PROJECTS</i>	43
1,000 GENOMES PROJECT	44
ARCHON X PRIZE IN GENOMICS	44
BASIC3 PROJECT	45
CANCER GENOME ATLAS	45
CANCER MOON SHOTS PROGRAM	46
CLARITY CHALLENGE	47
ENCODE PROJECT	47
GENOME IN A BOTTLE	47
MILLION VETERAN PROGRAM	48
NEUROMICS CONSORTIUM	48
CHAPTER 5 CLINICAL NEXT GENERATION SEQUENCING APPLICATIONS	50
INTRODUCTION	50
<i>TABLE 28 CLINICAL NEXT GENERATION SEQUENCING NEAR- TO MID-TERM APPLICATIONS</i>	50
CANCER APPLICATIONS	51
<i>TABLE 29 CANCER APPLICATIONS</i>	51

TOPIC	PAGE NO.
MENDELIAN DISORDERS APPLICATIONS	53
<i>TABLE 30 MENDELIAN DISORDERS APPLICATIONS</i>	53
SCREENING APPLICATIONS	54
<i>TABLE 31 SCREENING APPLICATIONS</i>	54
<i>TABLE 32 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN SCREENING</i>	57
INFECTIOUS DISEASE APPLICATIONS	57
<i>TABLE 33 INFECTIOUS DISEASE APPLICATIONS</i>	57
COMMON DISORDERS APPLICATIONS	59
<i>TABLE 34 COMMON DISORDER APPLICATIONS</i>	60
CHAPTER 6 CLINICAL NEXT GENERATION SEQUENCING INDUSTRY	63
INTRODUCTION	63
<i>TABLE 35 KEY SEGMENTS WITHIN THE NEXT GENERATION SEQUENCING CLINICAL INDUSTRY</i>	63
NEXT GENERATION SEQUENCING INSTRUMENT INDUSTRY	63
<i>TABLE 36 NEXT GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE</i>	64
<i>TABLE 37 NEXT GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013</i>	65
<i>TABLE 38 NEXT GENERATION SEQUENCING HIGH-THROUGHPUT INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013</i>	66
<i>TABLE 39 NEXT GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013</i>	67
NEXT GENERATION SEQUENCING TARGET ENRICHMENT INDUSTRY	68
<i>TABLE 40 NEXT GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY</i>	68
NEXT GENERATION SEQUENCING CLINICAL INFORMATICS INDUSTRY	69
<i>TABLE 41 NEXT GENERATION SEQUENCING CLINICAL INFORMATICS COMPANY POSITIONING</i>	70
CLINICAL LABORATORY INDUSTRY	71
<i>TABLE 42 LEADING U.S. CLINICAL LABORATORY IMPROVEMENT AMENDMENTS LABORATORIES WITH NEXT GENERATION SEQUENCING DIAGNOSTICS</i>	72
PRENATAL DIAGNOSTICS INDUSTRY	73
<i>TABLE 43 NEXT GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS INDUSTRY</i>	74
<i>TABLE 44 NORTH AMERICAN TEST COSTS AND PRICES (\$)</i>	75
<i>TABLE 45 NEXT GENERATION SEQUENCING-BASED NON-INVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2013 (%)</i>	76
<i>TABLE 46 NON-INVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS</i>	77
CLINICAL NEXT GENERATION SEQUENCING INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES	78
ACQUISITIONS	78
<i>TABLE 47 CLINICAL NEXT GENERATION SEQUENCING INDUSTRY ACQUISITIONS, 2011-2013</i>	79
STRATEGIC ALLIANCES	81
<i>TABLE 48 CLINICAL NEXT GENERATION SEQUENCING STRATEGIC ALLIANCES, 2011-2013</i>	82

TOPIC	PAGE NO.
CHAPTER 7 NEXT GENERATION SEQUENCING DIAGNOSTICS MARKETS	92
GROWTH DRIVING FORCES	92
TABLE 49 CLINICAL NEXT GENERATION SEQUENCING KEY GROWTH DRIVING FORCES, THROUGH 2018	92
GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET	93
TABLE 50 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE, THROUGH 2018 (\$ MILLIONS)	93
TABLE 51 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	95
TABLE 52 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	96
NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKETS	97
TABLE 53 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY MARKET SEGMENT, THROUGH 2018 (\$ MILLIONS)	97
TABLE 54 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	98
TABLE 55 GLOBAL CANCER NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	99
NEXT GENERATION SEQUENCING CARDIOVASCULAR DIAGNOSTIC MARKETS	100
TABLE 56 GLOBAL NEXT GENERATION SEQUENCING CARDIOVASCULAR DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	101
TABLE 57 GLOBAL NEXT GENERATION SEQUENCING CARDIOLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	102
NEXT GENERATION SEQUENCING MENDELIAN DISORDERS DIAGNOSTIC MARKETS	102
TABLE 58 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	103
TABLE 59 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	104
NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKETS	105
TABLE 60 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	105
TABLE 61 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	106
NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKETS	106
TABLE 62 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET FOR ALZHEIMER'S DISEASE BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	107
TABLE 63 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	108
NEXT GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKETS	108
TABLE 64 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	109
TABLE 65 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	110
NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKETS	110
TABLE 66 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	111
TABLE 67 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	112

TOPIC	PAGE NO.
NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKETS	113
<i>TABLE 68 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)</i>	113
<i>TABLE 69 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)</i>	114
NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN TYPING DIAGNOSTIC MARKETS	114
<i>TABLE 70 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN TYPING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)</i>	115
<i>TABLE 71 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN TYPING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)</i>	116
NEXT GENERATION SEQUENCING DIAGNOSTIC MARKETS BY GEOGRAPHY	116
<i>TABLE 72 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)</i>	117
NORTH AMERICA	117
<i>TABLE 73 NORTH AMERICAN NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2018 (\$ MILLIONS)</i>	117
EUROPE	118
<i>TABLE 74 EUROPEAN NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2018 (\$ MILLIONS)</i>	118
CHINA	119
<i>TABLE 75 CHINESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2018 (\$ MILLIONS)</i>	119
JAPAN	120
<i>TABLE 76 JAPANESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2018 (\$ MILLIONS)</i>	120
REST OF WORLD	121
<i>TABLE 77 REST OF WORLD NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2018 (\$ MILLIONS)</i>	121
CHAPTER 8 PATENTS	123
CLINICAL NEXT GENERATION SEQUENCING PATENTS	123
<i>TABLE 78 CLINICAL NEXT GENERATION SEQUENCING PATENTS, 2002-2012</i>	123
CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION	123
<i>TABLE 79 CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION, 2002-2012</i>	123
CLINICAL NEXT GENERATION SEQUENCING PATENT ISSUES	124
POSSIBILITY OF WHOLE-GENOME SEQUENCING VIOLATING SINGLE-GENE PATENTS	124
<i>TABLE 80 COMPOSITION OF MATTER CLAIMS RELATING TO SINGLE-GENE PATENTS</i>	125
STATUS OF SEQUENOM'S '054 PATENT LITIGATION	126
CHAPTER 9 COMPANY PROFILES	129
23ANDME INC.	129
<i>TABLE 81 DATA NEEDS</i>	129
ADAPTIVE BIOTECHNOLOGIES INC.	130
AGILENT TECHNOLOGIES INC.	131
ALMAC GROUP LTD.	132
AMBRY GENETICS	133
APPISTRY INC.	134

TOPIC	PAGE NO.
ARPEGGI INC.	134
ASTRID BIOSCIENCE GMBH	134
ASSURERX HEALTH	135
ASURAGEN INC.	135
BASE4INNOVATION LTD.	136
BECKMAN COULTER	136
BERRY GENOMICS CO. LTD.	137
BGI	138
BINA TECHNOLOGIES INC.	139
CARIS LIFE SCIENCES	140
CHRONIX BIOMEDICAL	140
CORIELL LIFE SCIENCES INC.	141
CORRELAGEN DIAGNOSTICS INC.	141
COUNSYL INC.	142
COURTAGEN LIFE SCIENCES INC.	142
CYPHER GENOMICS INC.	143
CYNVENIO BIOSYSTEMS INC.	143
DIOGENIX INC.	144
<i>TABLE 82 MULTIPLE SCLEROSIS DIAGNOSTIC TECHNOLOGIES</i>	144
DNA ELECTRONICS LTD.	145
DNA LINK	145
DNANEXUS INC.	145
ELECTRONIC BIOSCIENCES	146
EUROFINS MWG OPERON	146
EXOSOME DIAGNOSTICS INC.	147
EXPRESSION ANALYSIS INC.	148
FOUNDATION MEDICINE	149
GATC BIOTECH AG	149
GE HEALTHCARE	150
GENAPSYS	151
GENDX BV	151
GENEDX INC.	152
GENIA TECHNOLOGIES INC.	153
<i>TABLE 83 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING</i>	153
GENOLOGICS LIFE SCIENCES SOFTWARE	154
GENOMATIX SOFTWARE GMBH	154
GENOMEQUEST INC.	155
GENOMIC HEALTH INC.	156
GIGAGEN INC.	157
GNUBIO INC.	158
GOOD START GENETICS INC.	158
ILLUMINA INC.	159
INNOVATIONS EXCHANGE PTE LTD	161
INGENUITY SYSTEMS INC.	161
INVITAE	162
IREPORTOIRE	163
KAILOS GENETICS	163

TOPIC	PAGE NO.
KELLBENX INC.	163
KNOME INC.	164
LABORATORY CORPORATION OF AMERICA INC.	165
LABORATORY FOR MOLECULAR MEDICINE	165
LASERGEN INC.	166
LIFE TECHNOLOGIES INC.	166
LINGVITAE HOLDING AS	168
MACROGEN INC.	169
MAVERIX BIOMICS INC.	169
MD ANDERSON CANCER CENTER	170
MEDGENOME LABS PVT. LTD.	170
MEDOMICS LLC.	170
MULTIPLICOM NV	171
MYRIAD GENETICS INC.	172
NABSYS INC.	172
NATERA INC.	173
NEWGENE LTD.	173
NOBLEGEN BIOSCIENCES	174
NOVARTIS AG	174
OMICIA INC.	175
OMIXON BIOCOMPUTING KFT	176
ONCODNA SA	176
OXFORD GENE TECHNOLOGY	177
OXFORD NANOPORE TECHNOLOGIES	177
PACIFIC BIOSCIENCES OF CALIFORNIA INC.	178
PARABASE GENOMICS	180
PATHOGENICA	180
PATHOGENETIX	181
PERKIN ELMER INC.	182
PERSONAL GENOME DIAGNOSTICS INC.	184
PERSONALIS INC.	184
PICOSEQ	185
POPULATION GENETICS TECHNOLOGIES LTD.	185
<i>PORTABLE GENOMICS LLC</i>	187
PREVENTIONGENETICS INC.	187
QIAGEN	188
QUANTUMDX	189
RAINDANCE TECHNOLOGIES INC.	190
REAL TIME GENOMICS INC.	191
RESPONSE GENETICS INC.	191
ROCHE HOLDING AG	191
SCIGENOM LABS	193
SENGENICS INTERNATIONAL PTE LTD.	194
SEQUENOM INC.	194
SEQUENTA INC.	195
SEQUOIA GENETICS CO. LTD.	196
SEVEN BRIDGES GENOMICS INC.	196

TOPIC	PAGE NO.
SIEMENS AG	197
SILICON VALLEY BIOSYSTEMS	198
SISTEMAS GENOMICOS	198
SOFTGENETICS LLC	199
STATION X INC.	199
STRAND LIFE SCIENCES	199
STRATOS GENOMICS INC.	200
SUNDANCE DIAGNOSTICS INC.	200
SYAPSE	201
THERMO FISHER SCIENTIFIC, INC.	201
TRANSGENOMIC INC.	202
TROVAGENE INC.	202
WARP DRIVE BIO LLC	203
YIKON GENOMICS CO. LTD.	203
ZS GENETICS	204

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, THROUGH 2018 (\$ MILLIONS)	8
TABLE 1 REPORT SCOPE	11
TABLE 2 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE, THROUGH 2018 (\$ MILLIONS)	12
TABLE 3 KEY TECHNOLOGY DRIVERS FOR CLINICAL NEXT GENERATION SEQUENCING	13
TABLE 4 CLINICAL NEXT GENERATION SEQUENCING MARKET DRIVING FORCES	15
TABLE 5 CLINICAL NEXT GENERATION SEQUENCING APPLICATION STATUS	16
TABLE 6 KEY DIAGNOSTIC NEXT GENERATION SEQUENCING INDUSTRY PARTICIPANTS BY SECTOR	17
TABLE 7 DNA CHEMICAL BUILDING BLOCKS	20
TABLE 8 DNA TRANSLATION AND TRANSCRIPTION	20
TABLE 9 LONG-RANGE DNA STRUCTURE	21
TABLE 10 GENETIC VARIANT TYPES	22
TABLE 11 IMPORTANT MOLECULAR DIAGNOSTIC PLATFORMS BY COMPANY	23
TABLE 12 GENETIC TESTING EVOLUTION	24
TABLE 13 KEY NEAR- TO MID-TERM SEGMENTS FOR NEXT GENERATION SEQUENCING DIAGNOSTICS	25
TABLE 14 DNA SEQUENCING HISTORICAL TIMELINE, 1977-2013	27
TABLE 15 SEQUENCING TECHNOLOGY DEVELOPMENT, 1990-2013	32
TABLE 16 EFFECT OF NEW SEQUENCING TECHNOLOGIES ON COST AND TIME TO SEQUENCE A SINGLE HUMAN GENOME, 2001 AND 2013 (\$)	33
TABLE 17 SANGER SEQUENCING SUMMARY	33
TABLE 18 SANGER SEQUENCING IMPROVEMENTS	34
TABLE 19 NEXT GENERATION SEQUENCING TECHNOLOGIES	35
TABLE 20 ROCHE NEXT GENERATION SEQUENCING WORKFLOW	35
TABLE 21 ILLUMINA NEXT GENERATION SEQUENCING WORKFLOW	36
TABLE 22 LIFE TECHNOLOGIES NEXT GENERATION SEQUENCING WORKFLOW	37
TABLE 23 BENCHTOP SEQUENCER PLATFORMS , 2010-2012	38
TABLE 24 NEXT GENERATION SEQUENCING BIOINFORMATICS WORKFLOW	39
TABLE 25 SEQUENCE ANNOTATION STEPS	41
TABLE 26 FUTURE CHALLENGES FOR IMPLEMENTING CLINICAL NEXT GENERATION SEQUENCING	42
TABLE 27 TOP 10 CLINICAL NEXT GENERATION SEQUENCING PROJECTS	43
TABLE 28 CLINICAL NEXT GENERATION SEQUENCING NEAR- TO MID-TERM APPLICATIONS	50
TABLE 29 CANCER APPLICATIONS	51
TABLE 30 MENDELIAN DISORDERS APPLICATIONS	53
TABLE 31 SCREENING APPLICATIONS	54
TABLE 32 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN SCREENING	57
TABLE 33 INFECTIOUS DISEASE APPLICATIONS	57
TABLE 34 COMMON DISORDER APPLICATIONS	60
TABLE 35 KEY SEGMENTS WITHIN THE NEXT GENERATION SEQUENCING CLINICAL INDUSTRY	63
TABLE 36 NEXT GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL PHASE	64
TABLE 37 NEXT GENERATION SEQUENCING INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013	65

TABLE HEADING	PAGE NO.
TABLE 38 NEXT GENERATION SEQUENCING HIGH-THROUGHPUT INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013	66
TABLE 39 NEXT GENERATION SEQUENCING BENCHTOP INSTRUMENT COMPETITOR MARKET SHARE INSTALLED INSTRUMENT BASE, JUNE 2013	67
TABLE 40 NEXT GENERATION SEQUENCING-BASED TARGET ENRICHMENT INDUSTRY	68
TABLE 41 NEXT GENERATION SEQUENCING CLINICAL INFORMATICS COMPANY POSITIONING	70
TABLE 42 LEADING U.S. CLINICAL LABORATORY IMPROVEMENT AMENDMENTS LABORATORIES WITH NEXT GENERATION SEQUENCING DIAGNOSTICS	72
TABLE 43 NEXT GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS INDUSTRY	74
TABLE 44 NORTH AMERICAN TEST COSTS AND PRICES (\$)	75
TABLE 45 NEXT GENERATION SEQUENCING-BASED NON-INVASIVE PRENATAL DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2013 (%)	76
TABLE 46 NON-INVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS	77
TABLE 47 CLINICAL NEXT GENERATION SEQUENCING INDUSTRY ACQUISITIONS, 2011-2013	79
TABLE 48 CLINICAL NEXT GENERATION SEQUENCING STRATEGIC ALLIANCES, 2011-2013	82
TABLE 49 CLINICAL NEXT GENERATION SEQUENCING KEY GROWTH DRIVING FORCES, THROUGH 2018	92
TABLE 50 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY DISEASE, THROUGH 2018 (\$ MILLIONS)	93
TABLE 51 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	95
TABLE 52 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	96
TABLE 53 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY MARKET SEGMENT, THROUGH 2018 (\$ MILLIONS)	97
TABLE 54 GLOBAL NEXT GENERATION SEQUENCING CANCER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	98
TABLE 55 GLOBAL CANCER NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	99
TABLE 56 GLOBAL NEXT GENERATION SEQUENCING CARDIOVASCULAR DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	101
TABLE 57 GLOBAL NEXT GENERATION SEQUENCING CARDIOLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	102
TABLE 58 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	103
TABLE 59 GLOBAL NEXT GENERATION SEQUENCING MENDELIAN DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	104
TABLE 60 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	105
TABLE 61 GLOBAL NEXT GENERATION SEQUENCING METABOLIC AND IMMUNE DISORDER DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	106
TABLE 62 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET FOR ALZHEIMER'S DISEASE BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	107
TABLE 63 GLOBAL NEXT GENERATION SEQUENCING NEUROLOGY DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	108

TABLE HEADING	PAGE NO.
TABLE 64 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	109
TABLE 65 GLOBAL NEXT GENERATION SEQUENCING NEWBORN SCREENING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	110
TABLE 66 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	111
TABLE 67 GLOBAL NEXT GENERATION SEQUENCING PRENATAL DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	112
TABLE 68 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	113
TABLE 69 GLOBAL NEXT GENERATION SEQUENCING FOOD-BORNE ILLNESS DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	114
TABLE 70 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN TYPING DIAGNOSTIC MARKET BY TEST PURPOSE, THROUGH 2018 (\$ MILLIONS)	115
TABLE 71 GLOBAL NEXT GENERATION SEQUENCING HUMAN LEUKOCYTE ANTIGEN TYPING DIAGNOSTIC MARKET BY TEST COMPLEXITY, THROUGH 2018 (\$ MILLIONS)	116
TABLE 72 GLOBAL NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY REGION, THROUGH 2018 (\$ MILLIONS)	117
TABLE 73 NORTH AMERICAN NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2018 (\$ MILLIONS)	117
TABLE 74 EUROPEAN NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2018 (\$ MILLIONS)	118
TABLE 75 CHINESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2018 (\$ MILLIONS)	119
TABLE 76 JAPANESE NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2018 (\$ MILLIONS)	120
TABLE 77 REST OF WORLD NEXT GENERATION SEQUENCING DIAGNOSTIC MARKET BY APPLICATION, THROUGH 2018 (\$ MILLIONS)	121
TABLE 78 CLINICAL NEXT GENERATION SEQUENCING PATENTS, 2002-2012	123
TABLE 79 CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION, 2002-2012	123
TABLE 80 COMPOSITION OF MATTER CLAIMS RELATING TO SINGLE-GENE PATENTS	125
TABLE 81 DATA NEEDS	129
TABLE 82 MULTIPLE SCLEROSIS DIAGNOSTIC TECHNOLOGIES	144
TABLE 83 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING	153

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE CLINICAL NEXT GENERATION SEQUENCING MARKET BY DISEASE CLASS, 2012-2018 (\$ MILLIONS)	8